Final Operational Milestone #3

An Investigational New Drug (IND) Application was submitted to the U.S. Food and Drug Administration in the fourth quarter of 2019 under this award during this reporting period. The title of the application is “P-PSMA-101 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer”.